CHATTEM, INC D/B/A OPELLA

Lobbying for CHATTEM, INC D/B/A OPELLA · Healthcare related to nonprescription drugs and dietary supplements.

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 6, 2026

Expenses

$180,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

New Jersey

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 4

Health Issues

Nonprescription Drug Innovation Act (H.R.9774); dietary supplements; Generally Recognized as Safe (GRAS); Over the Counter Monograph User Fee Act (OMUFA); Generally Recognized as Safe and Effective (GRASE); HR.10336-Dietary Supplement Innovation Act; issues related to Rx to OTC Switch/PDUFA reauthorization.

Trade (domestic/foreign)

Tariffs.

Consumer Issues/Safety/Products

Illicit sale of OTCs on online retailer platforms.

Taxation/Internal Revenue Code

H.R.1219-To amend the Internal Revenue Code of 1986 to include over-the-counter oral healthcare products as qualified medical expenses which can be purchased with HSA and FSA funds.

Bills named in this filing 1

H.R. 9774
To amend the Federal Food, Drug, and Cosmetic Act to provide for expedited approval of priority nonprescription drugs, …

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.